Our high-definition, read-write platform interfaces with the spinal cord, brain, vagus nerve, and peripheral nerves at an unprecedented scale and enables a new class of precision-targeted neurostimulation medicines.
Our therapeutic platform is being developed for treatments where low-resolution neuromodulation therapies have failed and become therapies of last resort in chronic pain management and sensory-motor paralysis.
Our high-definition therapy platform delivers best-in-class selectivity and targeting and is being evaluated in multiple studies.